Fresenius Kabi USA flies complaint against NATCO Pharma
News

Fresenius Kabi USA flies complaint against NATCO Pharma

Natco Pharma intends to defend the matter accordingly

  • By IPP Bureau | April 19, 2024

NATCO Pharma Limited informed that Fresenius Kabi USA and Fresenius Kabi Deutschland have filed a complaint against Natco Pharma USA f/k/a Dash Pharmaceuticals in the District Court of Delaware relating to the marketing of Dash Pharmaceuticals Diazepam Injection prefilled syringe in the United States. Fresenius has not yet effectuated service of the complaint which is required to commence the lawsuit.

Natco Pharma intends to defend the matter accordingly.

Dash Pharmaceuticals LLC had been acquired by Natco Pharma, Inc. and Dash Pharmaceuticals LLC had changed its name to Natco Pharma USA LLC.

Upcoming E-conference

Other Related stories

Startup

Digitization